Neurocrine Biosciences price to free cash flow NBIX

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: 16.7×
8-year median: 35.7×
Against its 8-year history: 1st; percentile: 0 is its lowest day, 100 its highest
8-year range: 15.8× to 214×
Peer median: 27.7×

Neurocrine Biosciences' price to free cash flow is 16.7× as of Oct 23, 2026.

That is below its 8-year median of 35.7×, lower than on 99% of days in the last 8 years.

Over that time it ranged from 15.8× in Oct 2026 to 214× in Nov 2019.

The median for 10 biotech stocks of a similar size is 27.7×.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	16.7×	15.8×	23.7×
2025	24.4×	16.3×	34.9×
2024	32.1×	22.0×	38.9×
2023	33.7×	27.4×	66.8×
2022	64.9×	22.1×	92.8×
2021	25.1×	23.5×	49.3×
2020	38.4×	25.6×	126×
2019	122×	91.2×	214×
2018	88.3×	88.3×	136×

Against its peers

Companies in Biotechnology nearest Neurocrine Biosciences' size, closest first, today.

Company	Price to free cash flow
NBIXNeurocrine Biosciences	16.7×
HALOHalozyme Therapeutics	17.7×
EXELExelixis	13.6×
TECHBIO-TECHNE	43.2×
RGENRepligen	89.2×
KRYSKrystal Biotech	35.8×
INCYIncyte	12.2×
UTHRUnited Therapeutics	23.1×
ALNYAlnylam Pharmaceuticals	37.8×
ONCBeOne Medicines	32.3×
REGNRegeneron Pharmaceuticals	22.0×
Peer median	27.7×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on Neurocrine Biosciences

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.